SLC5A2 and metabolic disease: Growing evidence indicates that renal SGLT2 expression and activity do not follow a linear trajectory but instead display a biphasic pattern shaped by the hormonal, metabolic, and epigenetic perturbations associated with cardiovascular and metabolic diseases.